Table 3

Effect of TMP-SMX prophylaxis on 1-year PCP incidence and related mortality in the propensity score-matched population (n=470)

1-year PCP incidence1-year PCP-related mortality*
HR
(95% CI)
HR
(95% profile likelihood CI)
Univariable analysisMultivariable analysis†Univariable analysisMultivariable analysis‡
TMP-SMX prophylaxis0.07 (0.01 to 0.54)0.07 (0.01 to 0.53)0.07 (0.0005 to 0.55)0.08 (0.0006 to 0.71)
P value for HR0.0100.0100.0070.019
  • *Firth’s penalised maximum likelihood was used due to complete separation of outcome.

  • †Included age and MPA as covariates, and was also adjusted for clustering.

  • ‡Included age, GPA and MPA as covariates, and was also adjusted for clustering.

  • GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; PCP, pneumocystis pneumonia; TMP-SMX, trimethoprim-sulfamethoxazole.